Chlamydia pneumoniae Infection in Circulating Human Monocytes Is Refractory to Antibiotic Treatment
- 23 January 2001
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (3) , 351-356
- https://doi.org/10.1161/01.cir.103.3.351
Abstract
Background—Recovery of the intracellular bacterium Chlamydia pneumoniae from atherosclerotic plaques has initiated large studies on antimicrobial therapy in coronary artery disease. The basic concept that antibiotic therapy may eliminate and prevent vascular infection was evaluated in vitro and in vivo by examining the antibiotic susceptibility of C pneumoniae in circulating human monocytes, which are thought to transport chlamydiae from the respiratory tract to the vascular wall. Methods and Results—Blood monocytes (CD14+) from 2 healthy volunteers were obtained before and after oral treatment with azithromycin or rifampin and then inoculated with a vascular C pneumoniae strain and continuously cultured in the presence of the respective antibiotic. Progress of infection and chlamydial viability was assessed by immunogold-labeling and detection of C pneumoniae–specific mRNA transcripts. Circulating monocytes from patients undergoing treatment with experimental azithromycin for coronary artery disease were examined for C pneumoniae infection by cell culture. Antibiotics did not inhibit chlamydial growth within monocytes. Electron microscopy showed development of chlamydial inclusion bodies. Reverse transcription–polymerase chain reaction demonstrated continuous synthesis of chlamydial mRNA for 10 days without lysis of the monocytes. The in vivo presence of viable pathogen not eliminated by azithromycin was shown by cultural recovery of C pneumoniae from the circulating monocytes of 2 patients with coronary artery disease. Conclusions—C pneumoniae uses monocytes as a transport system for systemic dissemination and enters a persistent state not covered by an otherwise effective antichlamydial treatment. Prevention of vascular infection by antichlamydial treatment may be problematic: circulating monocytes carrying a pathogen with reduced antimicrobial susceptibility might initiate reinfection or promote atherosclerosis by the release of proinflammatory mediators.Keywords
This publication has 30 references indexed in Scilit:
- Detection ofChlamydia pneumoniaewithin Peripheral Blood Monocytes of Patients with Unstable Angina or Myocardial InfarctionThe Journal of Infectious Diseases, 2000
- Lack of Association between First Myocardial Infarction and Past Use of Erythromycin, Tetracycline, or DoxycyclineEmerging Infectious Diseases, 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Nitric Oxide Modulation of Neutrophil-Endothelium Interaction: Difference Between Arterial and Venous Coronary Bypass Grafts 11This work was supported in part by a grant from the Italian Ministry of University and Scientific Research, Rome, Italy.Journal of the American College of Cardiology, 1998
- Ultrastructural and molecular analyses of the persistence ofChlamydia trachomatis(serovar K) in human monocytesMicrobial Pathogenesis, 1997
- Increased incidence of Chlamydiaspecies within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular diseaseJournal of the American College of Cardiology, 1996
- The immunobiology and immunopathology of chlamydial infectionsAPMIS, 1995
- Demonstration of Chlamydia pneumoniae in Atherosclerotic Lesions of Coronary ArteriesThe Journal of Infectious Diseases, 1993
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992
- Persistent Infection with Chlamydia pneumoniae following Acute Respiratory IllnessClinical Infectious Diseases, 1992